Role of Skewed X-Chromosome Inactivation in Common Variable Immunodeficiency.

Common variable immunodeficiency HUMARA X-chromosome inactivation genetics next-generation sequencing

Journal

Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137

Informations de publication

Date de publication:
24 Jan 2024
Historique:
received: 13 11 2023
accepted: 16 01 2024
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 24 1 2024
Statut: epublish

Résumé

The term common variable immunodeficiency (CVID) encompasses a clinically diverse group of disorders, mainly characterized by hypogammaglobulinemia, insufficient specific antibody production, and recurrent infections. The genetics of CVID is complex, and monogenic defects account for only a portion of cases, typically <30%. Other proposed mechanisms include digenic, oligogenic, or polygenic inheritance and epigenetic dysregulation. In this study, we aimed to assess the role of skewed X-chromosome inactivation (XCI) in CVID. Within our cohort of 131 genetically analyzed CVID patients, we selected female patients with rare variants in CVID-associated genes located on the X-chromosome. Four patients harboring heterozygous variants in BTK (n = 2), CD40LG (n = 1), and IKBKG (n = 1) were included in the study. We assessed XCI status using the HUMARA assay and an NGS-based method to quantify the expression of the 2 alleles in mRNA. Three of the 4 patients (75%) exhibited skewed XCI, and the mutated allele was predominantly expressed in all cases. Patient 1 harbored a hypomorphic variant in BTK (p.Tyr418His), patient 3 had a pathogenic variant in CD40LG (c.288+1G>A), and patient 4 had a hypomorphic variant in IKBKG (p.Glu57Lys) and a heterozygous splice variant in TNFRSF13B (TACI) (c.61+2T>A). Overall, the analysis of our cohort suggests that CVID in a small proportion of females (1.6% in our cohort) is caused by skewed XCI and highly penetrant gene variants on the X-chromosome. Additionally, skewed XCI may contribute to polygenic effects (3.3% in our cohort). These results indicate that skewed XCI may represent another piece in the complex puzzle of CVID genetics.

Identifiants

pubmed: 38265673
doi: 10.1007/s10875-024-01659-z
pii: 10.1007/s10875-024-01659-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

54

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Weifenbach N, Schneckenburger AAC, Lötters S. Global distribution of common variable immunodeficiency (CVID) in the light of the UNDP Human Development Index (HDI): a preliminary perspective of a rare disease. J Immunol Res. 2020;2020:8416124.
doi: 10.1155/2020/8416124 pubmed: 32953893 pmcid: 7481957
Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203–11.
doi: 10.1111/cei.12178 pubmed: 23859429 pmcid: 3828823
Bonilla FA, Barlan I, Chapel H, Costa-Carvalho BT, Cunningham-Rundles C, de la Morena MT, et al. International consensus document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38–59.
doi: 10.1016/j.jaip.2015.07.025 pubmed: 26563668
Ameratunga R, Lehnert K, Woon ST, Gillis D, Bryant VL, Slade CA, et al. Review: diagnosing common variable immunodeficiency disorder in the era of genome sequencing. Clin Rev Allergy Immunol. 2018;54(2):261–8.
doi: 10.1007/s12016-017-8645-0 pubmed: 29030829
Peng XP, Caballero-Oteyza A, Grimbacher B. Common variable immunodeficiency: more pathways than roads to Rome. Annu Rev Pathol. 2023;18:283–310.
doi: 10.1146/annurev-pathmechdis-031521-024229 pubmed: 36266261
Ameratunga R, Edwards ESJ, Lehnert K, Leung E, Woon ST, Lea E, et al. The rapidly expanding genetic spectrum of common variable immunodeficiency-like disorders. J Allergy Clin Immunol Pract. 2023;11(6):1646–64.
doi: 10.1016/j.jaip.2023.01.048 pubmed: 36796510
Ameratunga R, Koopmans W, Woon ST, Leung E, Lehnert K, Slade CA, et al. Epistatic interactions between mutations of TACI (TNFRSF13B) and TCF3 result in a severe primary immunodeficiency disorder and systemic lupus erythematosus. Clin Transl Immunol. 2017;6(10):e159.
doi: 10.1038/cti.2017.41
Sic H, Speletas M, Cornacchione V, Seidl M, Beibel M, Linghu B, et al. An activating janus kinase-3 mutation is associated with cytotoxic t lymphocyte antigen-4-dependent immune dysregulation syndrome. Front Immunol. 2017;8:1824.
doi: 10.3389/fimmu.2017.01824 pubmed: 29375547 pmcid: 5770691
Dieli-Crimi R, Martínez-Gallo M, Franco-Jarava C, Antolin M, Blasco L, Paramonov I, et al. Th1-skewed profile and excessive production of proinflammatory cytokines in a NFKB1-deficient patient with CVID and severe gastrointestinal manifestations. Clin Immunol Orlando Fla. 2018;195:49–58.
doi: 10.1016/j.clim.2018.07.015
Li J, Jørgensen SF, Maggadottir SM, Bakay M, Warnatz K, Glessner J, et al. Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. Nat Commun. 2015;6:6804.
doi: 10.1038/ncomms7804 pubmed: 25891430
Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry B, et al. Genome-wide association identifies diverse causes of common variable immunodeficiency. J Allergy Clin Immunol. 2011;127(6):1360–1367.e6.
doi: 10.1016/j.jaci.2011.02.039 pubmed: 21497890 pmcid: 3646656
Rodríguez-Cortez VC, Del Pino-Molina L, Rodríguez-Ubreva J, Ciudad L, Gómez-Cabrero D, Company C, et al. Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naïve-to-memory B-cell transition. Nat Commun. 2015;6:7335.
doi: 10.1038/ncomms8335 pubmed: 26081581
Del Pino-Molina L, Rodríguez-Ubreva J, Torres Canizales J, Coronel-Díaz M, Kulis M, Martín-Subero JI, et al. Impaired CpG demethylation in common variable immunodeficiency associates with B cell phenotype and proliferation rate. Front Immunol. 2019;10:878.
doi: 10.3389/fimmu.2019.00878 pubmed: 31105700 pmcid: 6492528
Rodríguez-Ubreva J, Arutyunyan A, Bonder MJ, Del Pino-Molina L, Clark SJ, de la Calle-Fabregat C, et al. Single-cell atlas of common variable immunodeficiency shows germinal center-associated epigenetic dysregulation in B-cell responses. Nat Commun. 2022;13(1):1779.
doi: 10.1038/s41467-022-29450-x pubmed: 35365635 pmcid: 8975885
Savola P, Martelius T, Kankainen M, Huuhtanen J, Lundgren S, Koski Y, et al. Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica. 2020;105(12):2757–68.
doi: 10.3324/haematol.2019.220889 pubmed: 33256375
Papa R, Rusmini M, Schena F, Traggiai E, Coccia MC, Caorsi R, et al. Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). Clin Immunol Orlando Fla. 2021;231:108837.
doi: 10.1016/j.clim.2021.108837
Minks J, Robinson WP, Brown CJ. A skewed view of X chromosome inactivation. J Clin Invest. 2008;118(1):20–3.
doi: 10.1172/JCI34470 pubmed: 18097476
Batlle-Masó L, Rivière JG, Franco-Jarava C, Martín-Nalda A, Garcia-Prat M, Parra-Martínez A, et al. Molecular challenges in the diagnosis of X-linked chronic granulomatous disease: CNVs, intronic variants, skewed X-chromosome inactivation, and gonosomal mosaicism. J Clin Immunol. 2023;43(8):1953–1963.
Takada H, Kanegane H, Nomura A, Yamamoto K, Ihara K, Takahashi Y, et al. Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation. Blood. 2004;103(1):185–7.
doi: 10.1182/blood-2003-06-1964 pubmed: 12958074
Jones JR. Nonrandom X chromosome inactivation detection. Curr Protoc Hum Genet. 2014;80:971–9.7.7.
Futatani T, Watanabe C, Baba Y, Tsukada S, Ochs HD. Bruton’s tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females. Br J Haematol. 2001;114(1):141–9.
doi: 10.1046/j.1365-2141.2001.02905.x pubmed: 11472359
Conley ME, Farmer DM, Dobbs AK, Howard V, Aiba Y, Shurtleff SA, et al. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol. 2008;152(1):39–44.
doi: 10.1111/j.1365-2249.2008.03593.x pubmed: 18241230 pmcid: 2384053
Chen XF, Wang WF, Zhang YD, Zhao W, Wu J, Chen TX. Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: report from Shanghai, China (2000-2015). Medicine (Baltimore). 2016;95(32):e4544.
doi: 10.1097/MD.0000000000004544 pubmed: 27512878 pmcid: 4985333
Nonoyama S, Shimadzu M, Toru H, Seyama K, Nunoi H, Neubauer M, et al. Mutations of the CD40 ligand gene in 13 Japanese patients with X-linked hyper-IgM syndrome. Hum Genet. 1997;99(5):624–7.
doi: 10.1007/s004390050417 pubmed: 9150729
Mohammadi J, Liu C, Aghamohammadi A, Bergbreiter A, Du L, Lu J, et al. Novel mutations in TACI (TNFRSF13B) causing common variable immunodeficiency. J Clin Immunol. novembre. 2009;29(6):777–85.
doi: 10.1007/s10875-009-9317-5
Sg H, Dr P, Hj W, et al. Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem. 2005;280(8):7218-27.
Wang HY, Gopalan V, Aksentijevich I, Yeager M, Ma CA, Mohamoud YA, et al. A custom 148 gene-based resequencing chip and the SNP explorer software: new tools to study antibody deficiency. Hum Mutat. 2010;31(9):1080–8.
doi: 10.1002/humu.21322 pubmed: 20652909 pmcid: 2945728
Fusco F, Bardaro T, Fimiani G, Mercadante V, Miano MG, Falco G, et al. Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-kappaB activation. Hum Mol Genet. 2004;13(16):1763–73.
doi: 10.1093/hmg/ddh192 pubmed: 15229184
Gautheron J, Pescatore A, Fusco F, Esposito E, Yamaoka S, Agou F, et al. Identification of a new NEMO/TRAF6 interface affected in incontinentia pigmenti pathology. Hum Mol Genet. 2010;19(16):3138–49.
doi: 10.1093/hmg/ddq222 pubmed: 20529958
Frans G, van der Werff Ten Bosch J, Moens L, Gijsbers R, Changi-Ashtiani M, Rokni-Zadeh H, et al. Functional evaluation of an IKBKG variant suspected to cause immunodeficiency without ectodermal dysplasia. J Clin Immunol. 2017;37(8):801–10.
doi: 10.1007/s10875-017-0448-9 pubmed: 28993958
Bolduc V, Chagnon P, Provost S, Dubé MP, Belisle C, Gingras M, et al. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans. J Clin Invest. 2008;118(1):333–41.
doi: 10.1172/JCI33166 pubmed: 18097474
Shvetsova E, Sofronova A, Monajemi R, Gagalova K, Draisma HHM, White SJ, et al. Skewed X-inactivation is common in the general female population. Eur J Hum Genet EJHG. 2019;27(3):455–65.
doi: 10.1038/s41431-018-0291-3 pubmed: 30552425
Pereira G, Dória S. X-chromosome inactivation: implications in human disease. J Genet. 2021;100:63.
doi: 10.1007/s12041-021-01314-1 pubmed: 34553695
Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005;105(5):1881–90.
doi: 10.1182/blood-2003-12-4420 pubmed: 15358621
Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood. 1998;92(7):2421–34.
doi: 10.1182/blood.V92.7.2421 pubmed: 9746782
Hollenbaugh D, Wu LH, Ochs HD, Nonoyama S, Grosmaire LS, Ledbetter JA, et al. The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J Clin Invest. 1994;94(2):616–22.
doi: 10.1172/JCI117377 pubmed: 7518839 pmcid: 296138
de Saint BG, Tabone MD, Durandy A, Phan F, Fischer A, Le Deist F. CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization. Eur J Immunol. 1999;29(1):367–73.
doi: 10.1002/(SICI)1521-4141(199901)29:01<367::AID-IMMU367>3.0.CO;2-4
Smahi A, Courtois G, Vabres P, Yamaoka S, Heuertz S, Munnich A, et al. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature. 2000;405(6785):466–72.
doi: 10.1038/35013114 pubmed: 10839543
Fusco F, Pescatore A, Conte MI, Mirabelli P, Paciolla M, Esposito E, et al. EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-κB pathway can cause immunodeficiency and/or inflammation. Int Rev Immunol. 2015;34(6):445–59.
doi: 10.3109/08830185.2015.1055331 pubmed: 26269396
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51(6):1229–39.
pubmed: 1281384 pmcid: 1682906

Auteurs

Marina Garcia-Prat (M)

Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.

Laura Batlle-Masó (L)

Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Pompeu Fabra University (UPF), Barcelona, Catalonia, Spain.

Alba Parra-Martínez (A)

Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.

Clara Franco-Jarava (C)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Mónica Martinez-Gallo (M)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Aina Aguiló-Cucurull (A)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Janire Perurena-Prieto (J)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Neus Castells (N)

Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Medicine Genetics Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Blanca Urban (B)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Romina Dieli-Crimi (R)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain.

Pere Soler-Palacín (P)

Infection in Immunocompromised Pediatric Patients Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. pere.soler@vallhebron.cat.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Children's Hospital, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. pere.soler@vallhebron.cat.
Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain. pere.soler@vallhebron.cat.

Roger Colobran (R)

Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain. roger.colobran@vallhebron.cat.
Translational Immunology Research Group, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. roger.colobran@vallhebron.cat.
Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. roger.colobran@vallhebron.cat.
Department of Clinical and Molecular Genetics, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. roger.colobran@vallhebron.cat.
Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), Bellaterra, Catalonia, Spain. roger.colobran@vallhebron.cat.

Classifications MeSH